Part, Chapter, Paragraph
1 I, 2. 5 | are flexibly deployed over multiple tasks. Some contractual
2 II, 5. 1. 1 | cardio-vascular diseases.~ ~· Multiple Sclerosis~Multiple Sclerosis
3 II, 5. 1. 1 | Multiple Sclerosis~Multiple Sclerosis is a complex multifactorial
4 II, 5. 2. 3 | different coding practice and multiple hospital admissions for
5 II, 5. 2. 3 | different coding practice and multiple hospital admissions for
6 II, 5. 2. 3 | various factors such as multiple hospital admissions for
7 II, 5. 2. 6 | primary screenees of the Multiple Risk Factor Intervention
8 II, 5. 5. 3 | Longitudinal Study on Ageing~MSA~Multiple System Atrophy~PD~Parkinson’
9 II, 5. 5. 3 | 2007): Associations of multiple domains of self-esteem with
10 II, 5. 5. 3 | disease frequency trends from multiple surveys. ~Prevalence rates
11 II, 5. 5. 3 | epilepsy population. Thus, multiple sources of cases must be
12 II, 5. 5. 3 | 5.5.3.5 Multiple sclerosis~ ~
13 II, 5. 5. 3 | 5.3.5.1. Introduction~ ~Multiple sclerosis (MS) is a chronic
14 II, 5. 5. 3 | manifests itself with signs of multiple neurological dysfunctions (
15 II, 5. 5. 3 | examples follow. The Danish Multiple Sclerosis Registry (DMSR)
16 II, 5. 5. 3 | information on MS cases from multiple sources, including the National
17 II, 5. 5. 3 | to be a valuable tool for multiple assessments of MS epidemiological
18 II, 5. 5. 3 | The European Database for Multiple Sclerosis (EDMUS) has been
19 II, 5. 5. 3 | European Concerted Action for Multiple Sclerosis funded by the
20 II, 5. 5. 3 | The Norwegian National Multiple Sclerosis Registry was established
21 II, 5. 5. 3 | in 2001 at the Norwegian Multiple Sclerosis National Competence
22 II, 5. 5. 3 | 5.5.3.5.1. Prevalence of Multiple Sclerosis in selected EUGLOREH
23 II, 5. 5. 3 | Prevalence (per 100 000) of Multiple Sclerosis in selected EUGLOREH
24 II, 5. 5. 3 | Prevalence (per 100 000) of Multiple Sclerosis in selected EUGLOREH
25 II, 5. 5. 3 | Incidence (per 100 000/year) of Multiple Sclerosis in Europe~ ~ ~
26 II, 5. 5. 3 | rate was 2.6 in 1974–88. Multiple assessments carried out
27 II, 5. 5. 3 | national health care system, multiple large population-based assessments
28 II, 5. 5. 3 | epidemiological methods, multiple assessments and increased
29 II, 5. 5. 3 | 5.5.3.5.5. Proportion of Multiple Sclerosis patients by disease
30 II, 5. 5. 3 | 5.5.3.5.6. Proportion of Multiple Sclerosis patients by disease
31 II, 5. 5. 3 | and incidence rates where multiple assessments have been carried
32 II, 5. 5. 3 | methodology in time.~When multiple regression models were used
33 II, 5. 5. 3 | Directive on EU citizens with multiple sclerosis has not yet been
34 II, 5. 5. 3 | analysed; however, the onset of multiple sclerosis often occurs at
35 II, 5. 5. 3 | treatment towards people with multiple sclerosis within the European
36 II, 5. 5. 3 | by a British person with Multiple Sclerosis, Louise McVay.
37 II, 5. 5. 3 | supported by the European Multiple Sclerosis Platform and all
38 II, 5. 5. 3 | Sclerosis Platform and all EU Multiple Sclerosis Societies. Health
39 II, 5. 5. 3 | services in the management of Multiple Sclerosis;~· A shared agenda
40 II, 5. 5. 3 | Code of Good Practice” on Multiple Sclerosis and its reference
41 II, 5. 5. 3 | Code~· The European Map of Multiple Sclerosis, (ww g)~The European
42 II, 5. 5. 3 | care of MS patients. The multiple sclerosis therapy consensus
43 II, 5. 5. 3 | Services for People with Multiple Sclerosis in Europe by the
44 II, 5. 5. 3 | in Europe by the European Multiple Sclerosis Platform and RIMS,
45 II, 5. 5. 3 | RIMS, Rehabilitation in Multiple Sclerosis (Battaglia et
46 II, 5. 5. 3 | among foremost experts in Multiple Sclerosis Rehabilitation
47 II, 5. 5. 3 | people severely affected with multiple sclerosis ( Haffenden et
48 II, 5. 5. 3 | constitute the European Multiple Sclerosis Platform (EMSP).
49 II, 5. 5. 3 | international level, the Multiple Sclerosis International
50 II, 5. 5. 3(26)| treatment made to people with multiple sclerosis within the European
51 II, 5. 5. 3 | project entitled MS-ID (Multiple Sclerosis – Information
52 II, 5. 5. 3 | EU citizens affected by Multiple Sclerosis (MS). It will
53 II, 5. 5. 3 | prevalence and epidemiology of multiple sclerosis in Europe; good
54 II, 5. 5. 3 | Pascu I (2004): Report of multiple sclerosis centers. Cephalalgia
55 II, 5. 5. 3 | Services for Persons with Multiple Sclerosis in Europe~Baumhackl
56 II, 5. 5. 3 | al (2002): Prevalence of multiple sclerosis in Austria. Results
57 II, 5. 5. 3 | Epidemiologic survey of multiple sclerosis in Mures County,
58 II, 5. 5. 3 | 2001): The prevalence of multiple sclerosis, distribution
59 II, 5. 5. 3 | natural history of untreated multiple sclerosis in Iceland. A
60 II, 5. 5. 3 | E, Vela L et al (1998): Multiple sclerosis in Móstoles, central
61 II, 5. 5. 3 | Berkowicz T (2004): Report of multiple sclerosis center in Lodz.
62 II, 5. 5. 3 | 1995): Epidemiology of multiple sclerosis in Russia and
63 II, 5. 5. 3 | 71-76.~Boiko AN (1994): Multiple sclerosis prevalence in
64 II, 5. 5. 3 | Firnhaber W, Lauer K (eds): Multiple Sclerosis in Europe: An
65 II, 5. 5. 3 | Survival of patients with multiple sclerosis in Denmark: a
66 II, 5. 5. 3 | in Damish patients with multiple sclerosis. Brain 127:844-
67 II, 5. 5. 3 | Celius EG, Vandvik B (2001): Multiple sclerosis in Oslo, Norway:
68 II, 5. 5. 3 | a European database for multiple sclerosis. J Neurol Neurosurg
69 II, 5. 5. 3 | Establishment and use of multiple sclerosis registers – EDMUS.
70 II, 5. 5. 3 | progression of disability in multiple sclerosis. N Engl J Med
71 II, 5. 5. 3 | irreversible disability in multiple sclerosis: an amnesic process.
72 II, 5. 5. 3 | Nyland H, Midgard R (2004): Multiple sclerosis in Nord-Trøndelag
73 II, 5. 5. 3 | 2006): The prevalence of multiple sclerosis in the District
74 II, 5. 5. 3 | de Bono A, et al (2002): Multiple sclerosis in Malta in 1999:
75 II, 5. 5. 3 | 1998). Natural history of multiple sclerosis. In: Compston
76 II, 5. 5. 3 | Compston A (ed). McAlpine’s Multiple Sclerosis, 3rd edition.
77 II, 5. 5. 3 | Environmental factors and multiple sclerosis. Lancet 7;268-
78 II, 5. 5. 3 | G (2004). Mortality from multiple sclerosis in Austria 1970–
79 II, 5. 5. 3 | al (2004): Diagnosis of multiple sclerosis: comparison of
80 II, 5. 5. 3 | W, Lauer K (eds) (1994): Multiple Sclerosis in Europe: An
81 II, 5. 5. 3 | Treatment and Research in Multiple Sclerosis. Prague, Czech Republic
82 II, 5. 5. 3 | 1999): The prevalence of multiple sclerosis in Tayside, Scotland:
83 II, 5. 5. 3 | 1998): The prevalence of multiple sclerosis in the Leeds Health
84 II, 5. 5. 3 | prevalence and mortality of multiple sclerosis in Leeds. J Neurol
85 II, 5. 5. 3 | Symptomatic fatigue in multiple sclerosis. Arch Phys Med
86 II, 5. 5. 3 | Casetta I, et al (1996): Multiple sclerosis in Italy. A reappraisal
87 II, 5. 5. 3 | follow-up of the incidence of multiple sclerosis in Hordaland County,
88 II, 5. 5. 3 | Hansen G, et al (2000): Multiple sclerosis in North Norway,
89 II, 5. 5. 3 | people severely affected with multiple sclerosis. [On-line publication
90 II, 5. 5. 3 | Projection of the number of multiple sclerosis patients in germany].
91 II, 5. 5. 3 | Symptomatic Treatment of Multiple Sclerosis. Multiple Sclerosis
92 II, 5. 5. 3 | Treatment of Multiple Sclerosis. Multiple Sclerosis Therapy Consensus
93 II, 5. 5. 3 | Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol.
94 II, 5. 5. 3 | Horakova D (2004): Report of multiple sclerosis center at Charles
95 II, 5. 5. 3 | 1989): Epidemiology of multiple sclerosis in Czechoslovakia.
96 II, 5. 5. 3 | Crimi G (eds): An Update on Multiple Sclerosis. Monduzzi Editore,
97 II, 5. 5. 3 | 1988): Epidemiology of multiple sclerosis: incidence and
98 II, 5. 5. 3 | 1948–64 based on the Danish Multiple Sclerosis Registry. Acta
99 II, 5. 5. 3 | Hyllested K (1992): Incidence of multiple sclerosis in Denmark 1948-
100 II, 5. 5. 3 | Koch-Henriksen N (1999): The Danish Multiple Sclerosis Registry: a 50-
101 II, 5. 5. 3 | et al (2001). The Danish Multiple Sclerosis Registry. History,
102 II, 5. 5. 3 | Epidemiological investigation of multiple sclerosis in Slovenia. In:
103 II, 5. 5. 3 | Firnhaber W, Lauer K (eds): Multiple Sclerosis in Europe: An
104 II, 5. 5. 3 | Scheinberg LC (1988): Fatigue in multiple sclerosis. Arch Neurol 45:
105 II, 5. 5. 3 | neurological impairment in multiple sclerosis and expanded disability
106 II, 5. 5. 3 | Geographic disproportion of multiple sclerosis in Czechoslovakia
107 II, 5. 5. 3 | Firnhaber W, Lauer K (eds): Multiple Sclerosis in Europe: An
108 II, 5. 5. 3 | Defining the clinical course of multiple sclerosis: results from
109 II, 5. 5. 3 | international survey. National Multiple Sclerosis Society (USA):
110 II, 5. 5. 3 | Trials on New Agents in Multiple Sclerosis. Neurology 46:
111 II, 5. 5. 3 | 1996): Distinct patterns of multiple sclerosis pathology indicates
112 II, 5. 5. 3 | diagnostic criteria for multiple sclerosis: guidelines from
113 II, 5. 5. 3 | Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology
114 II, 5. 5. 3 | An epidemiologic study of multiple sclerosis in Northern Ireland.
115 II, 5. 5. 3 | study of primary progressive multiple sclerosis in Northern Ireland,
116 II, 5. 5. 3 | disability and handicap in multiple sclerosis: a population-based
117 II, 5. 5. 3 | variation in the prevalence of multiple sclerosis in Ireland, an
118 II, 5. 5. 3 | Middleton LT, Dean G (1991): Multiple sclerosis in Cyprus. J Neurol
119 II, 5. 5. 3 | N (1997): Prevalence of multiple sclerosis in Bulgaria. Neuroepidemiology
120 II, 5. 5. 3 | Care of the person with multiple sclerosis. In: Compston
121 II, 5. 5. 3 | Compston A. (ed). McAlpine’s Multiple sclerosis. China: Churchill
122 II, 5. 5. 3 | prevalence and incidence of multiple sclerosis: an epidemiological
123 II, 5. 5. 3 | Firnhaber W, Lauer K (eds): Multiple Sclerosis in Europe: An
124 II, 5. 5. 3 | JM (1997): Prevalence of multiple sclerosis in the province
125 II, 5. 5. 3 | Giroud M (2000): Incidence of multiple sclerosis in Dijon, France :
126 II, 5. 5. 3 | Neurol Res 22:156-159.~MSTCG (Multiple sclerosis therapy consensus
127 II, 5. 5. 3 | immunomodulatory therapy of multiple sclerosis. Update. Nervenarzt
128 II, 5. 5. 3 | Article in German)~MSTCG (Multiple sclerosis therapy consensus
129 II, 5. 5. 3 | H (2006): The Norwegian Multiple Sclerosis National Competence
130 II, 5. 5. 3 | Competence Centre and National Multiple Sclerosis registry—a resource
131 II, 5. 5. 3 | Prevalence and incidence of multiple sclerosis in Catania, Sicily.
132 II, 5. 5. 3 | Weinshenker BG (2000): Multiple sclerosis. N Engl J Med
133 II, 5. 5. 3 | persistent high frequency of multiple sclerosis in Croatia and
134 II, 5. 5. 3 | Epidemiological data of multiple sclerosis in the province
135 II, 5. 5. 3 | diagnostic criteria for multiple sclerosis: guidelines for
136 II, 5. 5. 3 | Increasing incidence of multiple sclerosis in South Lower
137 II, 5. 5. 3 | 1999): Epidemiology of multiple sclerosis in the region
138 II, 5. 5. 3 | Epidemiological aspects of multiple sclerosis: a comparative
139 II, 5. 5. 3 | Solinas G et al (2001): Multiple sclerosis epidemiology in
140 II, 5. 5. 3 | Increasing incidence of multiple sclerosis in the province
141 II, 5. 5. 3 | 2006): The epidemiology of multiple sclerosis in Europe. Eur
142 II, 5. 5. 3 | press): Epidemiology of multiple sclerosis. In: Raine CS,
143 II, 5. 5. 3 | McFarland HF, Hohlfeld H (eds). Multiple sclerosis. A comprehensive
144 II, 5. 5. 3 | Increasing frequency of multiple sclerosis in Padova, Italy:
145 II, 5. 5. 3 | M, Compston DAS (1995): multiple sclerosis in the North Cambridgeshire
146 II, 5. 5. 3 | the clinical diagnosis of multiple sclerosis. Neurology 26:
147 II, 5. 5. 3 | incidence and prevalence of multiple sclerosis in South East
148 II, 5. 5. 3 | 1993): Epidemiology of multiple sclerosis: a critical overview.
149 II, 5. 5. 3 | al (2004): Occurrence of multiple sclerosis in central Finland:
150 II, 5. 5. 3 | variation in the incidence of multiple sclerosis in Finland 1979-
151 II, 5. 5. 3 | Increasing prevalence of multiple sclerosis in Finland. Acta
152 II, 5. 5. 3 | Hakama M, Wikström J (2003): Multiple sclerosis in Finland: incidence
153 II, 5. 5. 3 | L (2001): Prevalence of multiple sclerosis in Västerbotten
154 II, 5. 5. 3 | and prevalence (1997): of multiple sclerosis in Västerbotten
155 II, 5. 5. 3 | Clinical characteristics of multiple sclerosis in Västerbotten
156 II, 5. 5. 3 | R (1999): Prevalence of multiple sclerosis in Valladolid,
157 II, 5. 5. 3 | al (2000): Prevalence of multiple sclerosis in the L’Aquila
158 II, 5. 5. 3 | transection in the lesions of multiple sclerosis. N Engl J Med
159 II, 5. 5. 3 | International Federation of Multiple Sclerosis) [on line publication
160 II, 5. 5. 3 | H (1994): Prevalence of multiple sclerosis in Flanders, Belgium.
161 II, 5. 5. 3 | variations in the prevalence of multiple sclerosis in French farmers.
162 II, 5. 5. 3 | epidemiological studies on multiple sclerosis. Neuroepidemiology
163 II, 5. 5. 3 | CDMS~Clinically Definite Multiple Sclerosis~CPMS~Clinically
164 II, 5. 5. 3 | CPMS~Clinically Probable Multiple Sclerosis~CP-MS~Chronic
165 II, 5. 5. 3 | CP-MS~Chronic Progressive Multiple Sclerosis~CNS~Central Nervous
166 II, 5. 5. 3 | Adjusted Life Years~DMSR~Danish Multiple Sclerosis Registry~EDSS~
167 II, 5. 5. 3 | Medical Agency~EMSP~European Multiple Sclerosis Platform~EU~European
168 II, 5. 5. 3 | Laboratory-Supported Definite Multiple Sclerosis~LSPMS~Laboratory-Supported
169 II, 5. 5. 3 | Laboratory-Supported Probable Multiple Sclerosis~MRI~Magnetic Resonance
170 II, 5. 5. 3 | Magnetic Resonance Imaging~MS~Multiple Sclerosis~MS-ID~Multiple
171 II, 5. 5. 3 | Multiple Sclerosis~MS-ID~Multiple Sclerosis Information Dividend~
172 II, 5. 5. 3 | Information Dividend~MSIF~Multiple Sclerosis International
173 II, 5. 5. 3 | International Federation~MSTCG~Multiple Sclerosis Therapy Consensus
174 II, 5. 5. 3 | PP-MS~Primary Progressive Multiple Sclerosis~PR-MS~Progressive-Relapsing
175 II, 5. 5. 3 | PR-MS~Progressive-Relapsing Multiple Sclerosis~RR-MS~Relapsing-Remitting
176 II, 5. 5. 3 | RR-MS~Relapsing-Remitting Multiple Sclerosis~SC~Subcutaneously~
177 II, 5. 5. 3 | SP-MS~Secondary Progressive Multiple Sclerosis~UK~United Kingdom~
178 II, 5. 5. 3 | typical symptoms of PD include multiple system atrophy (MSA), progressive
179 II, 5. 5. 3 | Rybicki BA, Johnson CC (2004): Multiple risk factors for Parkinson’
180 II, 5. 5. 3 | Epidemiological evidence on multiple system atrophy. J Neural
181 II, 5. 8. 3 | patients frequently have multiple chronic health conditions.
182 II, 5. 8. 3 | deaths from COPD and the multiple underlying causes (Furhman
183 II, 5. 8. 7 | in France, 1979-2002: a multiple cause analysis. Thorax 2006;
184 II, 5. 8. 7 | disease patients die from? A multiple cause coding analysis. Eur
185 II, 5. 9. 4 | phenomenon is probably related to multiple genetic and environmental
186 II, 5. 9. 4 | females (P=0.03). Analysis by multiple logistic regression showed
187 II, 6. 3. 3 | such as IDU and people with multiple sex partners.~ ~Almost 180
188 II, 7. 4. 2 | muscular strengths, revision of multiple medication). . Existing
189 II, 8. 2. 1 | disability is currently used. Multiple terms give rise to some
190 II, 8. 2. 1 | emerging perspective is that multiple and complex factors associated
191 II, 9 | 1993; Huang et al, 2000). Multiple pregnancies also carry a
192 II, 9 | higher preterm birth rate in multiple pregnancies (Ananth et al,
193 II, 9 | to be an interaction of multiple environmental and genetic
194 II, 9 | factors for STIs can include multiple sex partners and a weakened
195 II, 9. 1. 1 | characteristics/Risk factors~C: Multiple birth rate by number of
196 II, 9. 1. 1 | 2006): Preterm birth and multiple pregnancy in European countries
197 II, 9. 1. 1 | Magee BD (2004): Role of multiple births in very low birth weight
198 II, 9. 1. 2 | anomaly registers, using multiple sources of information to
199 II, 9. 1. 2 | 1993; Huang et al, 2000). Multiple pregnancies also carry a
200 II, 9. 1. 2 | higher preterm birth rate in multiple pregnancies (Ananth et al,
201 II, 9. 1. 2 | to be an interaction of multiple environmental and genetic
202 II, 9. 2. 4 | factors for STIs can include multiple sex partners and a weakened
203 II, 9. 3. 1 | fundamental in menopause. Multiple population-based studies
204 II, 9. 3. 2 | maternal conditions, the higher multiple birth rates caused by more
205 II, 9. 3. 2 | monitored, including the multiple birth rate, maternal age,
206 II, 9. 3. 2 | these treatments increase multiple births – which have higher
207 II, 9. 3. 2 | 2006): Preterm birth and multiple pregnancy in European countries
208 II, 9. 3. 2 | Magee BD (2004): Role of multiple births in very low birth weight
209 II, 9. 3. 3 | such as occasional sex with multiple partners without use of
210 II, 9. 3. 3 | for example, definition of multiple partners in the countries
211 II, 9. 3. 3 | Besides higher prevalence of multiple partners, men also report
212 II, 9. 3. 3 | notice a higher prevalence of multiple partners than the Finnish
213 II, 9. 4. 5 | pathology - the other 84% have multiple illnesses and/or rehabilitation
214 II, 9. 4. 5 | mostly due to the presence of multiple conditions (co-morbidities).
215 II, 9. 5. 1 | consider a lifespan and multiple role perspective.~ ~Gender-specific
216 II, 9. 5. 3 | and the administration of multiple prescription medication.
217 III, 10. 1 | combined exposures from multiple sources (food, air and water),
218 III, 10. 1 | extreme weather conditions~Multiple exposures~Leisure areas~
219 III, 10. 1 | Increased chemical sensitivity~multiple chemical exposures at low
220 III, 10. 2. 1 | data are collected from multiple sources by the Tobacco or
221 III, 10. 2. 1 | use started to grow among multiple groups, including problem
222 III, 10. 2. 1 | also often use cocaine and multiple other substances, marginalized
223 III, 10. 2. 1 | characterized by poly-drug use where multiple illicit and licit substances
224 III, 10. 2. 1 | problem drug users presents multiple health problems, including
225 III, 10. 2. 4 | with smoking on the risk of multiple myeloma, coronary heart
226 III, 10. 2. 4 | concurrent detection of multiple genomic variants that have
227 III, 10. 2. 4 | will be possible to assess multiple genomic and protein differences
228 III, 10. 3. 2 | Increased chemical sensitivity~multiple chemical exposures at low
229 III, 10. 3. 4 | are further aggravated by multiple stresses. Although there
230 III, 10. 4. 2 | expected effect. Exposure to multiple residues of pesticides via
231 III, 10. 4. 5 | 10.4.5. Multiple exposure: bathing water
232 III, 10. 4. 5 | provides opportunities for multiple exposure of human beings
233 III, 10. 5. 3 | are flexibly deployed over multiple tasks. Some contractual
234 III, 10. 5. 3 | institutions.~Diseases often have multiple causes. They are associated
235 III, 10. 5. 3 | Diseases most often have multiple causes. They are associated
236 IV, 11. 1. 3 | performance data results from multiple influences. On the supply
237 IV, 11. 1. 5 | 2003). Patients who face multiple interventions and have more
238 IV, 11. 5. 4 | organ donation can be due to multiple factors, including pressure
239 IV, 11. 6. 2 | disadvantages. For instance, multiple funds that can compete may
240 IV, 11. 6. 2 | perspective. Where there are multiple competing funds, as in the
241 IV, 11. 6. 2 | heavily on the presence of multiple funds, the insurance market
242 IV, 11. 6. 4 | in cases where there are multiple collection agents as in
243 IV, 12. 5 | objectives are built on multiple lines (Table 12.9).~ ~Table
244 IV, 12. 10 | policies and services to which multiple categories of groups-excluded
245 IV, 13. 2. 2 | DALYs. The total DALY for Multiple Sclerosis in Europe is 307
246 IV, 13. 5 | higher risk of suffering from multiple co-morbidities and experiencing
